Evaluation of glycolamide esters of indomethacin as potential cyclooxygenase-2 (COX-2) inhibitors

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 14, 2006, Pages 4820-4833

  Khanna, Smriti ^a   Madan, Manjula ^a   Vangoori, Akhila ^a   Banerjee, Rahul ^a   Thaimattam, Ram ^a   Jafar Sadik Basha, S K ^a   Ramesh, Mullangi ^a   Casturi, Seshagiri Rao ^a   Pal, Manojit ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

COX 1 and COX 2 inhibition; Indomethacin glycolamide esters; Structure activity relationship (SAR) study

Indexed keywords

[1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2 CHLOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2 FLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2 NITRO PHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2,3 DIMETHYLPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2,3,4 TRIFLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2,4 DIFLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (2,6 DICHLOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3 BROMOPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3 CHLORO 4 FLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3 FLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3 METHOXY PHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3 NITRO PHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (3,4 DIMETHOXY PHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 BROMO 2 METHYLPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 BROMOPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 CHLOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 FLUOROPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 IODO 2 METHYLPHENYLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID (4 METHYL THIAZOL 2 YLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID BENZO[1,3]DIOXOL 5 YLCARBAMOYLMETHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID BENZOTHIAZOL 2 YLCARBAMOYL METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID PYRIMIDIN 2 YLCARBAMOYL) METHYL ESTER; [1 (4 CHLOROBENZOYL) 5 METHOXY 2 METHYL 1H INDOL 3 YL]ACETIC ACID THIAZOL 2 YLCARBAMOYL) METHYL ESTER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN DERIVATIVE; LUMIRACOXIB; ROFECOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; EDEMA; HUMANS; HYDROGEN BONDING; INDOMETHACIN; MALE; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; SEMINAL VESICLES; SHEEP; STOMACH ULCER;

EID: 33646792175     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.03.023     Document Type: Article

References (52)

1. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davies B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., and Schnitzer T.J. N. Engl. J. Med. 343 (2000) 1520-1528
2. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson F.W., Burr A.M., Zhao W.W., Kent J.D., Lefkwith J.B., Verburg K.M., and Geis G.S. JAMA J. Am. Med. Assoc. 284 (2000) 1247-1255
3. Flower R.J., and Vane J.R. Nature 240 (1972) 410-411
4. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. J. Med.Chem. 40 (1997) 1347-1365
5. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromilish W., Ethier D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodger I., Tagari P., Therien M., Vickers P., Wong E., Xu L.-J., Young R.N., Zamboni R., Boyce S., Rupniak N., Forrest M., Visco D., and Patrick D. Bioorg. Med. Chem. Lett. 9 (1999) 1773-1778
6. Ducharme, Y.; Prasit, P.; Lenlanc, Y.; Leger, S.; Therien, M. World patent WO 95/00501 5 January 1995.
7. Talley J.A., Brown D.L., Carter J.S., Masferrer M.J., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., and Seibert K. J. Med. Chem. 43 (2000) 775-777
8. Scheen A.J. Rev. Med. Liege 59 (2004) 565-569
9. Kimmel S.E., Berlin J.A., Reilly M., Jaskowiak J., Kishel L., Chittams J., and Strom B.L. Ann. Intern. Med. 142 (2005) 157-164
10. Weber A., Casini A., Heine A., Kuhn D., Supuran C.T., Scozzafava A., and Klebe G. J. Med. Chem. 47 (2004) 550-557
11. Supuran C.T., Casini A., Mastrolorenzo A., and Scozzafava A. Mini-Rev. Med. Chem. 4 (2004) 625-632
12. For indolealkanoates, see:. Leblanc Y., Black W.C., Chan C.C., Charleson S., Delorme D., Denis D., Gauthier J.Y., Grimm E.L., Gordon R., Guay D., Hamel P., Kargman S., Lau C.K., Mancini J., Ouellet M., Percival D., Roy P., Skorey K., Tagari P., Vickers P., Wong E., Xu L., and Prasit P. Bioorg. Med. Chem. Lett. 6 (1996) 731-736
13. Kalgutkar A.S., Marnett A.B., Crews B.C., Remmel R.P., and Marnett L.J. J. Med. Chem. 43 (2000) 2860-2870
14. Palomer A., Cabre F., Pascual J., Campos J., Trujillo M.A., Entrena A., Gallo M.A., Garcia L., Mauleon D., and Espinosa A. J. Med. Chem. 45 (2002) 1402-1411
15. Luong C., Miller A., Barnett J., Chow J., Ramesha C., and Browner M.F. Nat. Struct. Biol. 3 (1996) 927-933
16. For biphenylalkanoate, see:. Bayly C.I., Black W.C., Leger S., Ouimet N., Ouellet M., and Percival M.D. Bioorg. Med. Chem. Lett. 6 (1999) 307-312
17. Portevin B., Tordjman C., Pastoureau P., Bonnet J., and Nanteuil G.De. J. Med. Chem. 43 (2000) 4582-4593
18. For reviews on COX-2 inhibitors, see:. Carter J.S. Exp. Opin. Ther. Patents 8 (1997) 21-24
19. Reitz D.B., and Isakson P.C. Curr. Pharm. Des. 1 (1995) 211-220
20. For recent examples, see:. Almansa C., Alfon J., Arriba A.F.de., Cavalcanti F.L., Escamilla I., Gomez L.A., Miralles A., Soliva R., Bartroli J., Carceller E., Merlos M., and Garcia-Rafanell J. J. Med. Chem. 46 (2003) 3463-3475
21. Hu W., Guo Z., Chu F., Bai A., Yi X., Cheng G., and Li J. Bioorg. Med. Chem. 11 (2003) 1153-1160
22. O'Neal, J. M.; Masferrer, J. L. World patent WO 2003013655 A2 20 Feb 2003; Chem. Abstr. 2003, 138, 163607.
23. Rao P.N.P., Li M., Amini H., Habeeb A.G., and Knaus E.E. J. Med. Chem. 46 (2003) 4872-4882
24. Black W.C., Bayly C., Belley M., Chan C.C., Charleson S., Denis D., Gauthier J.Y., Gordon R., Guay D., Kargman S., Lau C.K., Leblanc Y., Mancini J., Ouellet M., Percival D., Roy P., Skorey K., Tagari P., Vickers P., Wong E., Xu L., and Prasit P. Bioorg. Med. Chem. Lett. 6 (1996) 725-730
25. Marnett L.J., and Kalgutkar A.M. Curr. Opin. Chem. Biol. 2 (1998) 482-490
26. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Marnett A.B., Kozak K.R., Remmel R.P., and Marnett L.J. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 925-930
27. Kozak K.R., Prusakiewicz J.J., Rowlinson S.W., and Marnett L.J. Bioorg. Med. Chem. Lett. (2002) 1315-1318
28. Olgen S., Akaho E., and Nebioglu D. Eur. J. Med. Chem. 36 (2001) 747-770
29. Pal M., Veeramaneni V.R., Nagabelli M., Kalleda S.R., Misra P., Casturi S.R., and Yeleswarapu K.R. Bioorg. Med. Chem. Lett. 13 (2003) 1639-1643
30. Pal M., Madan M., Srinivas P., Pattabiraman V.R., Kalleda S.R., Akhila V., Ramesh M., Rao Mamidi N.V.S., Casturi S.R., Malde A., Gopalakrishnan B., and Yeleswarapu K.R. J. Med. Chem. 46 (2003) 3975-3984
31. Pal M., Rao V.V., Srinivas P., Murali N., Akhila V., Premkumar M., Rao C.S., Misra P., Ramesh M., and Rao Y.K. Indian J. Chem. 42B (2003) 593-601
32. Pal M., Rao V.V., Kumar S., Lohray V.B., and Yeleswarapu K.R. J. Indian Chem. Soc. 80 (2003) 1095-1101
33. Pal M., Rao V.V., Kumar S., Vangoori A., Mullangi R., Misra P., Rajjak S.A., Lohray V.B., Casturi S.R., and Yeleswarapu K.R. Lett. Drug Des. Discovery 2 (2005) 329-340
34. Pal M., Dakarapu R., and Padakanti S. J. Org. Chem. 69 (2004) 2913-2916
35. Pal M., Subramanian V., Batchu V.R., and Dager I. Synlett (2004) 1965-1969
36. Sahu N.P., Pal C., Mandal N.B., Banerjee S., Raha M., Kundu A.P., Basu A., Ghosh M., Roy K., and Bandyopadhyay S. Bioorg. Med. Chem. 10 (2002) 1687-1694
37. Bundgaard H., and Nielsen N.M. J. Med. Chem. 30 (1987) 451-454
38. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., and Chan C.-C. Inflamm. Res. 45 (1996) 68-74
39. Chan C.-C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guoy D., Hill R., Li C.-S., Mancini J., Penneton M., Prasit P., Rasori R., Riendeau D., Roy P., Targari P., Vickers P., Wong E., and Rodger I.W. J. Pharmacol. Exp. Ther. 274 (1995) 1531-1537
40. Loll P.J., Picot D., Ekabo O., and Garavito R.M. Biochemistry 35 (1996) 7330-7340
41. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., and Stallings W.C. Nature 384 (1996) 644-648
42. Nielsen N.M., and Bundgaard H. J. Med. Chem. 32 (1989) 727-734
43. Khan M.S.Y., and Khan R.M. Indian J. Chem. 41B (2002) 2172-2175
44. Muller P., Dammann H.G., and Simon B. Z. Rheumatol. 45 (1986) 68-70
45. Furberg C.D., Psaty B.M., and FitzGerald G.A. Circulation 111 (2005) 249
46. max and AUC of compound 32 were tested in mice and then compared with those of indomethacin. Comparable PK parameters observed for 32 and indomethacin indicated that less GI toxicity displayed by 32 was not due to its lower bioavailability in Swiss albino mice.
47. Walter M.F., Jacob R.F., Day C.A., Dahlborg R., Weng Y., et al. Atherosclerosis 177 (2004) 235-243
48. SYBYL6.92 Molecular Modeling software, Tripos Associates, Inc.: 1669, South Hanley Road, Suite 303, St. Louis, Missouri, MO 63144-2913, USA.
49. Hemler H., Lands W.E.M., and Smith W.L. J. Biol. Chem. 251 (1976) 5575-5579
50. Cromlish W.A., Payette P., Culp S.A., Ouellet M., Percival M.D., and Kennedy B.P. Arch. Biochem. Biophys. 314 (1994) 193-199
51. Copeland R.A., Williams J.M., Giannaras J., Nurnberg S., Covington M., Pinto D., Pick S., and Trzaskos J.M. Proc. Natl. Acad. Sci U.S.A. 91 (1994) 11202-11206
52. Bradford M.A. Anal. Biochem. 72 (1976) 248